drugset / Trial / NCT07444307
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NaSequentialOpen-labelTreatment
Summary
This study is a single-arm, open-label clinical study designed to evaluate the safety and tolerability of QT-019B in subjects with refractory SLE and to determine the RD. The study has two phases: dose escalation and dose expansion, with a planned enrollment of 18-24 subjects.
Timeline
- Start
- 2025-12-15
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QT-019B | Cell therapy | 1 cells/kg | Other |
| Subject | QT-019B | Cell therapy | 3 cells/kg | Other |